The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe Implantable Cardioverter Defibrillator(ICD)therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants. This study will assess therapies in Medtronic pacemaker, defibrillator, and cardiac resynchronization therapy devices. The first therapy is for reducing unnecessary pacing in pacemaker patients. The second therapy provides pacing therapy in an attempt to stop fast or life threatening ventricular arrhythmias in lieu of delivering a defibrillation shock. The third therapy is a diagnostic measurement of a patient's fluid status and provides the physician information on the patient's heart failure status. The study will also assess the time to a patient's first defibrillation shock and will verify that the shock was for a fast or life threatening ventricular rhythm.
The OMNI results demonstrate the importance of Medtronic's ongoing efforts to increase adoption of evidence based shock-reduction programming strategies. Longer VF NID (number of intervals to detect in the VF zone) should be utilized with the Anti-tachycardia Pacing (ATP) During Charging Feature. ATP during Charging allows physicians to treat with ATP without delay to shock. Therefore, VF NID may be extended to allow episodes the chance to self-terminate immediately to shock by use of the ATP during the charging feature.
Study Type
OBSERVATIONAL
Enrollment
3,032
Southern Arizona Health Care System
Tucson, Arizona, United States
Arkansas Cardiology PA (Little Rock AR)
Little Rock, Arkansas, United States
California Heart Medical Associates
Fresno, California, United States
Apex Cardiology
Inglewood, California, United States
Scripps Green Hospital Scripps Clinic Torrey Pines
La Jolla, California, United States
Implanted Systems Frequencies
Frequencies of implanted systems were measured among patients who were implanted with a device (IPT, ICD or CRT-D).
Time frame: Baseline
Implantable Pulse Generator (IPG) Device Baseline Programming Frequencies.
Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P\&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost.
Time frame: Baseline
ICD/CRT-D Device Baseline Programming Frequencies
ICD/CRT-D baseline programming, pacing mode and detection. Pacing mode is based on the NASPE/BPEG Generic (NBG) Pacemake coding which includes: I, the chambers paced (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); II, the chambers sensed (V= Ventricle, A=Atrium, D=Dual (A\&V), O=None); III, the mode of response (T=Triggered, I=Inhibited, D=Dual Triggered/Inhibited, O=None); IV, the programmable functions(R=Rate Modulated, C=Communicating, M=Multiprogrammable, P=Simple Programmable, O=None); V, the antitachycardia functions (O=None, P=Paced, S=Shocks, D=Dual (P\&S)). In addition, MVP (managed ventricular pacing) is a mode that promotes AV conduction by reducing or eliminating unnecessary RV pacing but maintains dual chamber ventricular support in the event that AV conduction is lost.
Time frame: Baseline
ICD/CRT-D Device Baseline Programming Measurements
ICD/CRT-D baseline programming measurements, detection interval. Implanted Cardioverter/Defibrillator paces a patient's heart in a tachyarrhythmia prevention-pacing mode. Detection intervals are used to detect atrial tachyarrhythmia. Detection Intervals are programmable heart rate thresholds. R-R intervals that are less than the VT or VF detection intervals (in ms) are considered evidence of VT or VF, respectively. R-R intervals that are between the FVT and the VF detection intervals are considered evidence of FVT. Thus, these detection interval thresholds demarcate rate zones of detection. The rate zones are used to determine the type of therapy applied once detection occurs.
Time frame: Baseline
AV Block Status by Device Type at 6 and 12 Months.
Frequencies of subject with AV block over time between ICD and Implantable Pulse Generator(IPG) study participants.
Time frame: 12 months post enrollment
AV Block Status by Severity of Historical AV Block
Frequencies of Subjects with AV Block Over Time by Severity of Historical AV Block
Time frame: 4 years post implant
Summary of ATP Episodes Within All Treated Episodes
Evaluate the utility of the Antitachycardia Pacing (ATP) During Charging feature of the device.
Time frame: 4 years post enrollment
Compare First Shock Rate Between Medtronic "PainFREE" Programming and "SCD-HeFT" Programming in Primary Prevention Study Participants.
First shock rate for VF and FVT zones was estimated using Kaplan-Meier method. OMNI "PainFREE" definition: programming combinations that result in ATP therapy for ventricular tachycardia (VT) at cycle lengths \<320 ms. Programming at cycle lengths ≥320 ms were not mandated. OMNI "SCD-HeFT" definition: programming combinations that result in shock therapy only for arrhythmias at cycle lengths of \<320 ms or faster and no therapy for arrhythmias at cycle lengths ≥320 ms.
Time frame: 4 years post implant
Frequencies of Subjects With OptiVol Trends and Disease Progression.
Estimate the correlation between OptiVol trends and disease progression. A subject's disease status was said to have progressed if: 1. The NYHA classification number increases (example: I to II), or 2. The LVEF decreases by at least 20% (relative difference) and by at least a 5% absolute difference, or 3. The subject expires A subject who crossed OptiVol threshold since last visit was regarded as 'crossed threshold'.
Time frame: 4 years post implant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Northern California Heart Care
Larkspur, California, United States
Mission Internal Medical Group
Mission Viejo, California, United States
Orange County Heart Institute & Research Center
Orange, California, United States
Foothill Cardiology
Pasadena, California, United States
Desert Cardiology Center / Desert Cardiology Medical Group Consultants
Rancho Mirage, California, United States
...and 103 more locations